HSS Journal

, Volume 5, Issue 2, pp 169–177

Overlap Between Systemic Lupus Erythematosus and Kikuchi Fujimoto Disease

A Clinical Pathology Conference held by the Department of Rheumatology at Hospital for Special Surgery
  • Jessica K. Gordon
  • Cynthia Magro
  • Theresa Lu
  • Robert Schneider
  • April Chiu
  • Richard R. Furman
  • Garron Solomon
  • Anne Bass
  • Doruk Erkan
Clinical Pathology Conference

References

  1. 1.
    Jang YJ, Park KH Seok HJ (2000) Management of Kikuchi’s disease using glucocorticoid. J. Laryngol. Otol. 114:709–11PubMedCrossRefGoogle Scholar
  2. 2.
    Rezai K, Kuchipudi S, Chundi V (2004) Kikuchi–Fujimoto disease: hydroxychloroquine as a treatment. Clin. Infect. Dis 39:e124–e126PubMedCrossRefGoogle Scholar
  3. 3.
    Lawrence RC, Helmick CG, Arnett FC (1998) Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 41:778–799PubMedCrossRefGoogle Scholar
  4. 4.
    Jimenez S, Cervera R, Font J (2003) The epidemiology of systemic lupus erythematosus. Clin. Rev. Allergy Immunol. 25:3–12PubMedCrossRefGoogle Scholar
  5. 5.
    El-Ramahi KM, Karrar A, Ali MA (1994) Kikuchi disease and its association with systemic lupus erythematosus. Lupus 3:409–11PubMedCrossRefGoogle Scholar
  6. 6.
    Goldblatt F, Andrews J, Russell A, Isenberg D (2008) Association of Kikuchi–Fujimoto’s disease with SLE. Rheumatology 47:554–555Google Scholar
  7. 7.
    Eisner MD, Amory J, Mullaney B (1996) Necrotizing lymphadenitis associated with systemic lupus erythematosus. Semin. Arthritis Rheum. 26:1–6CrossRefGoogle Scholar
  8. 8.
    Ohshima K, Karube K, Hamasaki M (2004) Apoptosis- and cell cycle-associated gene expression profiling of histiocytic necrotising lymphadenitis. Eur. J. Haematol. 72:322–9PubMedCrossRefGoogle Scholar
  9. 9.
    Kato K, Ohshima K, Anzai K (2001) Elevated serum-soluble Fas ligand in histiocytic necrotizing lymphadenitis. Int. J. Hematol. 73:84–6PubMedCrossRefGoogle Scholar
  10. 10.
    Kozyrev SV, Lewén S, Reddy PM (2007) Structural insertion/deletion variation in IRF5 is associated with a risk haplotype and defines the precise IRF5 isoforms expressed in systemic lupus erythematosus. Arthritis Rheum 56:1234–41PubMedCrossRefGoogle Scholar
  11. 11.
    Niewold TB, Kelly JA, Flesch MH (2008) Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum. 58:2481–7PubMedCrossRefGoogle Scholar
  12. 12.
    Graham RR, Kyogoku C, Sigurdsson S, et al. (2007) Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci U S A. 104:6758–6763Google Scholar
  13. 13.
    Kirou KA, Mavragani CP, Crow MK (2007) Activation of typeI interferon in systemic lupus erythematosus. Expert Rev. Clin. Immunol. 3:579–588Google Scholar
  14. 14.
    Barrat FJ, Meeker T, Gregorio J, et al. (2005) Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 202:1131–1139Google Scholar
  15. 15.
    Cella M, Jarrossay D, Facchetti F (1999) Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med. 5:919–923PubMedCrossRefGoogle Scholar
  16. 16.
    Qu C, Moran TM, Randolph GJ (2003) Autocrine type I IFN and contact with endothelium promote the presentation of influenza A virus by monocyte-derived APC. J. Immunol 170:1010–1018PubMedGoogle Scholar
  17. 17.
    Tsang WY, Chan JK, Ng CS (1994) Kikuchi’s lymphadenitis. A morphologic analysis of 75 cases with special reference to unusual features. Am. J. Surg. Pathol. 18:219–231PubMedCrossRefGoogle Scholar
  18. 18.
    Heremans H, Billiau A, Colombatti A (1978) Interferon treatment of NZB mice: accelerated progression of autoimmune disease. Infect. Immun. 21:925–930PubMedGoogle Scholar
  19. 19.
    Braun D, Geraldes P, Demengeot J (2003) Type I interferon controls the onset and severity of autoimmune manifestations in lpr mice. J. Autoimmun. 20:15–25PubMedCrossRefGoogle Scholar
  20. 20.
    Adam C, Thoua Y, Ronco P (1980) The effect of exogenous interferon: acceleration of autoimmune and renal diseases in (NZB/W) F1 mice. Clin. Exp. Immunol. 40:373–382PubMedGoogle Scholar
  21. 21.
    Mathian A, Weinberg A, Gallegos M (2005) IFN-{alpha} induces early lethal lupus in preautoimmune (New Zealand Black × New Zealand White) F1 but Not in BALB/c Mice. J. Immunol. 174:2499–2506PubMedGoogle Scholar
  22. 22.
    Santiago-Raber ML, Baccala R, Haraldsson KM (2003) Type-I Interferon Receptor Deficiency Reduces Lupus-like Disease in NZB Mice. J. Exp. Med. 197:777–788PubMedCrossRefGoogle Scholar
  23. 23.
    Hron JD, Peng SL (2004) Type I IFN protects against murine lupus. J. Immunol. 173:2134–2142PubMedGoogle Scholar
  24. 24.
    Baechler EC, Batliwalla FM, Karypis G (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 100:2610–2615PubMedCrossRefGoogle Scholar
  25. 25.
    Crow MK, Kirou KA, Wohlgemuth J (2003) Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 36:481–490PubMedCrossRefGoogle Scholar
  26. 26.
    Bennett L, Palucka AK, Arce E (2003) Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197:711–723PubMedCrossRefGoogle Scholar
  27. 27.
    Kirou KA, Lee C, George S (2004) Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum. 50:3958–3967PubMedCrossRefGoogle Scholar
  28. 28.
    Farkas L, Beiske K, Lund-Johansen F (2001) Plasmacytoid dendritic cells (natural interferon- {{alpha}}/{beta}-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am. J. Pathol. 159:237–243PubMedGoogle Scholar
  29. 29.
    Blomberg S, Eloranta ML, Cederblad B (2001) Presence of cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosus. Lupus 10:484–490PubMedCrossRefGoogle Scholar
  30. 30.
    Nakano H, Yanagita M, Gunn MD (2001) CD11c(+)B220(+)Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J. Exp. Med. 194:1171–1178PubMedCrossRefGoogle Scholar
  31. 31.
    Yoneyama H, Matsuno K, Toda E (2005) Plasmacytoid DCs help lymph node DCs to induce anti-HSV CTLs. J. Exp. Med. 202:425–435PubMedCrossRefGoogle Scholar
  32. 32.
    Shiow LR, Rosen DB, Brdickova N, et al., CD69 acts downstream of interferon-[alpha]/[beta] to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 2006; 440: 540–544.Google Scholar

Copyright information

© Hospital for Special Surgery 2009

Authors and Affiliations

  • Jessica K. Gordon
    • 1
  • Cynthia Magro
    • 2
  • Theresa Lu
    • 1
  • Robert Schneider
    • 3
  • April Chiu
    • 4
  • Richard R. Furman
    • 5
  • Garron Solomon
    • 2
  • Anne Bass
    • 1
  • Doruk Erkan
    • 1
  1. 1.Department of RheumatologyHospital for Special SurgeryNew YorkUSA
  2. 2.Department of DermatopathologyWeill-Cornell Medical College-New York Presbyterian HospitalNew YorkUSA
  3. 3.Department of RadiologyHospital for Special SurgeryNew YorkUSA
  4. 4.Department of PathologyWeill-Cornell Medical College-New York Presbyterian HospitalNew YorkUSA
  5. 5.Division of Hematology and OncologyWeill-Cornell Medical College–New York Presbyterian HospitalNew YorkUSA

Personalised recommendations